Tags

Type your tag names separated by a space and hit enter

A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine.
Surg Neurol Int 2019; 10:131SN

Abstract

Background

Leptomeningeal metastases (LM) pose the most difficult form of cancer metastasis to treat and portend a poor prognosis. Standard treatment has yet to be established, and intrathecal chemotherapy and whole- brain radiotherapy are administered on an empirical basis.

Case Description

We report on a 46-year-old woman with LM from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. She was suffering from intractable headaches, severe nausea and vomiting, and cerebellar ataxia. Contrast-enhanced magnetic resonance imaging (MRI) revealed diffuse enhancement of the meninges, mainly in the posterior cranial fossa, and compression of the cerebellum by the profoundly thickened meninges. The first step in the treatment was decompression of the posterior cranial fossa to relieve intracranial hypertension. After surgery, her symptoms immediately improved. The second step was treatment with lapatinib at 1250 mg and capecitabine 1200 mg, which dramatically improved her symptoms and disappeared diffuse abnormal signal enhancement on MRI.

Conclusion

We treated a patient with LM from primary HER2-positive breast cancer who responded well to lapatinib plus capecitabine.

Authors+Show Affiliations

Departments of Neurosurgery Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.Departments of Neurosurgery Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.Departments of Microbiology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.Departments of Neurosurgery Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

31528467

Citation

Nakao, Takayuki, et al. "A Case of Leptomeningeal Metastases of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer That Responded Well to Lapatinib Plus Capecitabine." Surgical Neurology International, vol. 10, 2019, p. 131.
Nakao T, Okuda T, Fujita M, et al. A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine. Surg Neurol Int. 2019;10:131.
Nakao, T., Okuda, T., Fujita, M., & Kato, A. (2019). A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine. Surgical Neurology International, 10, p. 131. doi:10.25259/SNI-106-2019.
Nakao T, et al. A Case of Leptomeningeal Metastases of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer That Responded Well to Lapatinib Plus Capecitabine. Surg Neurol Int. 2019;10:131. PubMed PMID: 31528467.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine. AU - Nakao,Takayuki, AU - Okuda,Takeshi, AU - Fujita,Mitsugu, AU - Kato,Amami, Y1 - 2019/06/28/ PY - 2019/02/08/received PY - 2019/05/22/accepted PY - 2019/9/19/entrez PY - 2019/9/19/pubmed PY - 2019/9/19/medline KW - Breast cancer KW - Capecitabine KW - Human epidermal growth factor receptor 2 KW - Lapatinib KW - Leptomeningeal metastases SP - 131 EP - 131 JF - Surgical neurology international JO - Surg Neurol Int VL - 10 N2 - Background: Leptomeningeal metastases (LM) pose the most difficult form of cancer metastasis to treat and portend a poor prognosis. Standard treatment has yet to be established, and intrathecal chemotherapy and whole- brain radiotherapy are administered on an empirical basis. Case Description: We report on a 46-year-old woman with LM from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. She was suffering from intractable headaches, severe nausea and vomiting, and cerebellar ataxia. Contrast-enhanced magnetic resonance imaging (MRI) revealed diffuse enhancement of the meninges, mainly in the posterior cranial fossa, and compression of the cerebellum by the profoundly thickened meninges. The first step in the treatment was decompression of the posterior cranial fossa to relieve intracranial hypertension. After surgery, her symptoms immediately improved. The second step was treatment with lapatinib at 1250 mg and capecitabine 1200 mg, which dramatically improved her symptoms and disappeared diffuse abnormal signal enhancement on MRI. Conclusion: We treated a patient with LM from primary HER2-positive breast cancer who responded well to lapatinib plus capecitabine. SN - 2229-5097 UR - https://www.unboundmedicine.com/medline/citation/31528467/A_case_of_leptomeningeal_metastases_of_human_epidermal_growth_factor_receptor_2-positive_breast_cancer_that_responded_well_to_lapatinib_plus_capecitabine L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31528467/ DB - PRIME DP - Unbound Medicine ER -